Davis Lara E, Ryan Christopher W
Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L586, Portland, OR, 97239, USA,
Curr Treat Options Oncol. 2015 Jun;16(6):25. doi: 10.1007/s11864-015-0346-4.
High-risk soft tissue sarcomas (STS) are defined as large (>5 cm), intermediate/high-grade tumors and can carry a >50 % risk of death from metastases. A regimen of preoperative chemoradiation immediately addresses issues of both local control and micrometastases and should be considered for patients with high-risk STS of the extremities. While acute wound healing complications are more likely to occur, these are most always manageable and reversible, as opposed to the long-term complications associated with higher radiation doses and larger fields required for post-operative therapy. Preoperative treatment also yields potential prognostic information from pathologic treatment response, and quantitative imaging methods hold promise to detect early treatment effect. Definitive evidence of survival benefit from neoadjuvant therapy has been elusive, but a large body of experience has accumulated at dedicated centers where this approach is utilized. Whenever possible, it is imperative that patients with high-risk STS be enrolled on well-designed clinical trials. Treatment planning and administration requires a coordinated multidisciplinary approach that should be undertaken in high-volume centers with expertise in the management of sarcomas.
高危软组织肉瘤(STS)被定义为较大(>5厘米)的中/高级别肿瘤,发生转移导致死亡的风险可能超过50%。术前放化疗方案可立即解决局部控制和微转移问题,对于四肢高危STS患者应予以考虑。虽然急性伤口愈合并发症更有可能发生,但这些大多总能得到控制且可逆,这与术后治疗所需更高辐射剂量和更大照射野相关的长期并发症不同。术前治疗还能从病理治疗反应中得出潜在的预后信息,定量成像方法有望检测早期治疗效果。新辅助治疗带来生存获益的确切证据一直难以捉摸,但在采用这种方法的专业中心已积累了大量经验。只要有可能,高危STS患者必须参加精心设计的临床试验。治疗规划和实施需要采用协调一致的多学科方法,这应由在肉瘤管理方面具有专业知识的大容量中心来进行。